Logo image of LVTX

LAVA THERAPEUTICS NV (LVTX) Stock Overview

NASDAQ:LVTX - NL0015000AG6 - Common Stock

1.57 USD
+0.01 (+0.64%)
Last: 9/9/2025, 8:00:00 PM

LVTX Key Statistics, Chart & Performance

Key Statistics
52 Week High2.09
52 Week Low0.85
Market Cap41.31M
Shares26.31M
Float17.71M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.05
PEN/A
Fwd PEN/A
Earnings (Next)12-08 2025-12-08
IPO03-25 2021-03-25
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


LVTX short term performance overview.The bars show the price performance of LVTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15 20

LVTX long term performance overview.The bars show the price performance of LVTX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60

The current stock price of LVTX is 1.57 USD. In the past month the price increased by 3.29%. In the past year, price decreased by -8.72%.

LAVA THERAPEUTICS NV / LVTX Daily stock chart

LVTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.72B
AMGN AMGEN INC 12.84 150.72B
GILD GILEAD SCIENCES INC 14.96 143.64B
VRTX VERTEX PHARMACEUTICALS INC 23.4 101.65B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 63.20B
REGN REGENERON PHARMACEUTICALS 12.19 58.99B
ARGX ARGENX SE - ADR 82.74 46.94B
ONC BEONE MEDICINES LTD-ADR 6.15 41.74B
INSM INSMED INC N/A 31.11B
BNTX BIONTECH SE-ADR N/A 24.54B
NTRA NATERA INC N/A 24.21B
BIIB BIOGEN INC 8.97 21.05B

About LVTX

Company Profile

LVTX logo image LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company is headquartered in Utrecht, Utrecht and currently employs 34 full-time employees. The company went IPO on 2021-03-25. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

Company Info

LAVA THERAPEUTICS NV

Yalelaan 60

Utrecht UTRECHT NL

Employees: 34

LVTX Company Website

LVTX Investor Relations

Phone: 31630003035

LAVA THERAPEUTICS NV / LVTX FAQ

What is the stock price of LAVA THERAPEUTICS NV today?

The current stock price of LVTX is 1.57 USD. The price increased by 0.64% in the last trading session.


What is the ticker symbol for LAVA THERAPEUTICS NV stock?

The exchange symbol of LAVA THERAPEUTICS NV is LVTX and it is listed on the Nasdaq exchange.


On which exchange is LVTX stock listed?

LVTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for LAVA THERAPEUTICS NV stock?

8 analysts have analysed LVTX and the average price target is 1.4 USD. This implies a price decrease of -10.99% is expected in the next year compared to the current price of 1.57. Check the LAVA THERAPEUTICS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is LAVA THERAPEUTICS NV worth?

LAVA THERAPEUTICS NV (LVTX) has a market capitalization of 41.31M USD. This makes LVTX a Nano Cap stock.


How many employees does LAVA THERAPEUTICS NV have?

LAVA THERAPEUTICS NV (LVTX) currently has 34 employees.


What are the support and resistance levels for LAVA THERAPEUTICS NV (LVTX) stock?

LAVA THERAPEUTICS NV (LVTX) has a support level at 1.56 and a resistance level at 1.58. Check the full technical report for a detailed analysis of LVTX support and resistance levels.


Is LAVA THERAPEUTICS NV (LVTX) expected to grow?

The Revenue of LAVA THERAPEUTICS NV (LVTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the LVTX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy LAVA THERAPEUTICS NV (LVTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does LAVA THERAPEUTICS NV (LVTX) stock pay dividends?

LVTX does not pay a dividend.


When does LAVA THERAPEUTICS NV (LVTX) report earnings?

LAVA THERAPEUTICS NV (LVTX) will report earnings on 2025-12-08.


What is the Price/Earnings (PE) ratio of LAVA THERAPEUTICS NV (LVTX)?

LAVA THERAPEUTICS NV (LVTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.05).


What is the Short Interest ratio of LAVA THERAPEUTICS NV (LVTX) stock?

The outstanding short interest for LAVA THERAPEUTICS NV (LVTX) is 0.32% of its float. Check the ownership tab for more information on the LVTX short interest.


LVTX Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to LVTX. When comparing the yearly performance of all stocks, LVTX turns out to be only a medium performer in the overall market: it outperformed 52.01% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

LVTX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to LVTX. While LVTX seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LVTX Financial Highlights

Over the last trailing twelve months LVTX reported a non-GAAP Earnings per Share(EPS) of -1.05. The EPS decreased by -15.38% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -69.12%
ROE -190.76%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-3.23%
Sales Q2Q%N/A
EPS 1Y (TTM)-15.38%
Revenue 1Y (TTM)77.01%

LVTX Forecast & Estimates

8 analysts have analysed LVTX and the average price target is 1.4 USD. This implies a price decrease of -10.99% is expected in the next year compared to the current price of 1.57.

For the next year, analysts expect an EPS growth of 1.84% and a revenue growth -100% for LVTX


Analysts
Analysts47.5
Price Target1.4 (-10.83%)
EPS Next Y1.84%
Revenue Next Year-100%

LVTX Ownership

Ownership
Inst Owners36.96%
Ins Owners0.17%
Short Float %0.32%
Short Ratio0.54